+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations
M

Actively Recruiting

Researchers are evaluating the efficacy and safety of Eloralintide LY3841136 for adults with osteoarthritis of the knee who are overweight or obese and experiencing knee pain. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess how well Eloralintide works in reducing body weight and improving knee pain. The trial is sponsored by Eli Lilly and Company and includes two independent studies under a master protocol. Participants will receive once-weekly subcutaneous injections of either Eloralintide or placebo. The study includes parallel treatment arms comparing Eloralintide to placebo in adults with osteoarthritis knee pain and weight concerns. Treatment lasts for approximately 64 weeks, with dosing and assessments occurring regularly. The study also allows for a total participation duration of about 75 weeks, including screening. During the trial, participants will undergo various assessments including measurements of body weight, knee pain using the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale, physical function, blood pressure, inflammatory markers, and walking distance. Researchers will monitor medication use and collect data on quality of life and biochemical markers. Safety and pharmacokinetics of Eloralintide are also tracked throughout the study.

Age: 18Years +All GendersPhase 3
147 locations
C

Actively Recruiting

Hypertension, or high blood pressure, affects over 100 million people in the US and raises the risk of serious health problems like stroke, heart attack, and kidney disease. This research evaluates two approaches to improve blood pressure control in diverse populations served by safety-net primary care clinics. The study aims to address barriers to effective hypertension management by engaging patients, clinicians, and health systems to implement evidence-based strategies. The trial compares two interventions remote blood pressure monitoring RBPM using standardized measurement and treatment protocols, and RBPM combined with multilevel intensification interventions MII that involve team-based approaches such as clinician decision support, medication adherence monitoring, use of combination pills, and formulary changes. These interventions are rolled out sequentially across multiple sites using a cluster randomized stepped-wedge design to allow comparison and implementation assessment. Participants will be monitored over time with assessments including systolic blood pressure measurements every three months up to 54 months, and patient-reported outcomes like activation, medication adherence, and trust in medical care at several intervals. Researchers will evaluate treatment intensification, blood pressure control, and fidelity to interventions. The study collects both quantitative and qualitative data to understand effectiveness and implementation success, with total follow-up lasting up to 54 months.

Age: 18Years +All GendersPhase Not Applicable
7 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations
O

Actively Recruiting

Researchers are evaluating QRX003 lotion 4% as an addition to standard care, including systemic therapy, in people with Netherton syndrome. The study aims to assess the safety, tolerability, and effectiveness of this topical treatment over a 12-week period. This open-label trial involves participants who have a confirmed clinical diagnosis of Netherton syndrome and lesions on their arms or lower legs. Participants will apply QRX003 lotion once or twice daily for 12 weeks. Two treatment groups will compare once-daily morning application to twice-daily application. The lotion contains a 4% active serine protease inhibitor. The study is designed as a single-group, non-randomized trial with no placebo or blinding involved. During the study, participants will be monitored for changes in skin condition using measures such as Investigator Global Assessment IGA scores, affected skin surface area, and itch severity WI-NRS. Subject satisfaction with treatment and the need for rescue therapy will also be assessed. Safety will be closely monitored through reports of adverse events and local skin reactions. The total participation duration is up to 16 weeks, including treatment and follow-up assessments.

Age: 14Years +All GendersPhase 2Phase 3
4 locations
O

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of QRX003 lotion, a 4% serine protease inhibitor, in treating Netherton syndrome NS. This study focuses on applying the lotion twice daily to affected skin areas excluding the scalp, covering about 50% or more of the body surface. The trial is conducted at multiple centers and follows an open-label design, including participants aged 4 years and older with genetically confirmed NS. Participants will apply QRX003 lotion twice daily for 12 weeks to their NS-affected skin areas. The treatment area excludes the scalp and covers approximately half or more of the body surface. This single-group study does not include a placebo or comparator group. The study spans 12 weeks of active treatment with the lotion. During the trial, participants will be monitored for improvement using several measures, including the Investigator Global Assessment IGA score to track skin condition changes, and other itch and global impression scores at week 12. Safety and tolerability will also be assessed throughout the treatment period. The total participation duration aligns with the 12-week treatment, with follow-up evaluations at the studys end.

Age: 4Years +All GendersPhase 2Phase 3
8 locations